NICE rejects Keytruda, asks for more info
The decision, which is for HNSCC, brings the UK “further out of step with clinical practice in the rest of the world.”
Read More
Tag: HNSCC
AZ’ Imfinzi fails in head and neck cancer trial
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Read More
Keytruda extends survival in first-line head and neck cancer trial
MSD’s Keytruda significantly extended overall survival when used as monotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients expressing PD-L1.
Read More
AZ resumes enrolment in head and neck cancer trials
AstraZeneca has resumed new patient enrolment in Phase III trials testing the potential of its anti-PD-L1 immunotherapy durvalumab for head and neck cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
